Gender differences in platelet reactivity in diabetic patients receiving dual antiplatelet therapy.

[1]  E. Barbato,et al.  Impact of platelet reactivity on 5-year clinical outcomes following percutaneous coronary intervention: a landmark analysis , 2018, Journal of Thrombosis and Thrombolysis.

[2]  B. Lindahl,et al.  Sex Differences in Treatments, Relative Survival, and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry , 2017, Journal of the American Heart Association.

[3]  Peter L Duffy,et al.  Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. , 2017, International journal of cardiology.

[4]  Peter L Duffy,et al.  Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) , 2017, Circulation. Cardiovascular interventions.

[5]  H. Suryapranata,et al.  Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients. , 2016, Thrombosis research.

[6]  S. Pocock,et al.  Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.

[7]  H. Suryapranata,et al.  Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy , 2016, Journal of Thrombosis and Thrombolysis.

[8]  H. Suryapranata,et al.  Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy , 2016, Cardiovascular Drugs and Therapy.

[9]  H. Suryapranata,et al.  Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. , 2016, Vascular pharmacology.

[10]  H. Suryapranata,et al.  Impact of diabetes on fibrinogen levels and its relationship with platelet reactivity and coronary artery disease: A single-centre study. , 2015, Diabetes research and clinical practice.

[11]  Samin K. Sharma,et al.  The Shifting Pendulum for DAPT After PCI: Balancing Long-Term Risks for Bleeding and Thrombosis. , 2015, Journal of the American College of Cardiology.

[12]  H. Suryapranata,et al.  Recent Advances in Optimal Adjunctive Antithrombotic Therapy in STEMI Patients Undergoing Primary Angioplasty: An Overview. , 2015, Current vascular pharmacology.

[13]  L. Cheskin,et al.  Sex differences in short-term and long-term all-cause mortality among patients with ST-segment elevation myocardial infarction treated by primary percutaneous intervention: a meta-analysis. , 2014, JAMA internal medicine.

[14]  G. De Luca,et al.  Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management: A Meta-analysis of Randomized Trials , 2014, Journal of cardiovascular pharmacology.

[15]  G. De Luca,et al.  Vitamin D deficiency is independently associated with the extent of coronary artery disease , 2014, European journal of clinical investigation.

[16]  A. Budaj,et al.  The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial , 2014, European heart journal.

[17]  B. Giusti,et al.  Gender and Anti-thrombotic Therapy: from Biology to Clinical Implications , 2014, Journal of Cardiovascular Translational Research.

[18]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[19]  G. Stone,et al.  Gender-related differences in outcome after BMS or DES implantation in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the DESERT cooperation. , 2013, Atherosclerosis.

[20]  G. Maurer,et al.  Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. , 2013, International journal of cardiology.

[21]  T. Lindahl,et al.  Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. , 2013, Journal of the American College of Cardiology.

[22]  A. Nicolucci,et al.  Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes , 2013, Advances in Therapy.

[23]  P. Gurbel,et al.  Platelet reactivity and thrombogenicity in postmenopausal women , 2013, Menopause.

[24]  M. Vidali,et al.  Role of the laboratory in monitoring patients receiving dual antiplatelet therapy , 2012, International journal of laboratory hematology.

[25]  G. De Luca,et al.  Uric acid does not affect the prevalence and extent of coronary artery disease. Results from a prospective study. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[26]  I. Spoletini,et al.  A GENS-based approach to cardiovascular pharmacology: impact on metabolism, pharmacokinetics and pharmacodynamics. , 2011, Therapeutic delivery.

[27]  F. Zijlstra,et al.  Effect of gender difference on platelet reactivity , 2011, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.

[28]  P. Gurbel,et al.  Clopidogrel response variability and the advent of personalised antiplatelet therapy , 2011, Thrombosis and Haemostasis.

[29]  D. Angiolillo,et al.  Review article: Platelet abnormalities in diabetes mellitus , 2010, Diabetes & vascular disease research.

[30]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[31]  D. Angiolillo,et al.  Impact of race and gender on antithrombotic therapy , 2010, Thrombosis and Haemostasis.

[32]  D. Dudek,et al.  Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry. , 2010, Atherosclerosis.

[33]  D. Dudek,et al.  Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb–IIIa inhibitors: insights from the EGYPT cooperation , 2010, Journal of Thrombosis and Thrombolysis.

[34]  R. Abbate,et al.  High Residual Platelet Reactivity After Clopidogrel Loading and Long-Term Clinical Outcome After Drug-Eluting Stenting for Unprotected Left Main Coronary Disease , 2009, Circulation.

[35]  D. Dudek,et al.  Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors. , 2009, Atherosclerosis.

[36]  A. Gori,et al.  Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy. , 2009, American journal of clinical pathology.

[37]  Keshav R. Nayak,et al.  Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. , 2009, The American journal of cardiology.

[38]  E. Antman,et al.  Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.

[39]  J. Segal,et al.  Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men , 2006, Journal of the American Medical Association (JAMA).

[40]  Gianni Tognoni,et al.  Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-Analysis of Randomized Controlled Trials , 2006, JAMA.

[41]  J. Ottervanger,et al.  Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty. , 2005, American heart journal.

[42]  J. Ottervanger,et al.  Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction study. , 2004, American heart journal.

[43]  P. Ramwell,et al.  Sex and age differences in human platelet aggregation , 1975, Nature.

[44]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[45]  B. Jilma,et al.  The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention. , 2015, Clinical science.